Quantitative analysis of CD133-positive cells by flow cytometry has generally found them to be present at low and sometimes barely detectable levels in human gliomas, glioma sphere cultures, and established glioma cell lines [2, 37–40], consistent with the assumption that CSCs are a rare cell population in solid tumors. This evidence concerns the gene PROM1 and glioma.